GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Thanks for chiming in.

>That was my point a while back when I mentioned the ever closing gap between transgenic expression level and newer CHO cell line costs.<

Expression level is a separate issue from glycosylation variants. (The latter is a red herring, IMO.)

The point you raised about improving yields in CHO cells remains a consequential one. To my knowledge, most of the recent improvement in protein yields from traditional bioreactor technology has been in the area of mAbs, specifically. Perhaps this is one of the reasons GTC has not made as much headway attracting partners for mAb programs as they have in attracting partners for non-mAb programs.

GTC’s CD137 program will an interesting one to watch. If GTC can ink an impressive partnership deal for this candidate, it will go a long way toward showing that GTC can still be a significant player in mAbs. Regards, Dew